

Peter E Czabotar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637991/publications.pdf>

Version: 2024-02-01

96
papers

17,900
citations

50566

48
h-index

42259

96
g-index

103
all docs

103
docs citations

103
times ranked

24164
citing authors

#	ARTICLE	IF	CITATIONS
1	The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. <i>Nature Reviews Cancer</i> , 2022, 22, 45-64.	12.8	144
2	Ion currents through Kir potassium channels are gated by anionic lipids. <i>Nature Communications</i> , 2022, 13, 490.	5.8	9
3	The Bak core dimer focuses triacylglycerides in the membrane. <i>Biophysical Journal</i> , 2022, 121, 347-360.	0.2	1
4	Structure of the BAK-activating antibody 7D10 bound to BAK reveals an unexpected role for the $\hat{L}1\hat{L}2$ loop in BAK activation. <i>Cell Death and Differentiation</i> , 2022, 29, 1757-1768.	5.0	4
5	Membrane permeabilization is mediated by distinct epitopes in mouse and human orthologs of the necroptosis effector, MLKL. <i>Cell Death and Differentiation</i> , 2022, 29, 1804-1815.	5.0	22
6	Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors. <i>Frontiers in Chemistry</i> , 2022, 10, 861209.	1.8	11
7	Basis for drug selectivity of plasmepsin IX and X inhibition in <i>Plasmodium falciparum</i> and vivax. <i>Structure</i> , 2022, 30, 947-961.e6.	1.6	9
8	Human RIPK3 C-lobe phosphorylation is essential for necroptotic signaling. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	9
9	Biophysical Characterization of Pro-apoptotic BimBH3 Peptides Reveals an Unexpected Capacity for Self-Association. <i>Structure</i> , 2021, 29, 114-124.e3.	1.6	10
10	The regulation of necroptosis by post-translational modifications. <i>Cell Death and Differentiation</i> , 2021, 28, 861-883.	5.0	70
11	Yeast- and antibody-based tools for studying tryptophan C-mannosylation. <i>Nature Chemical Biology</i> , 2021, 17, 428-437.	3.9	17
12	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X _L and BCL-2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5447-5469.	2.9	5
13	Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. <i>Nature Communications</i> , 2021, 12, 2211.	5.8	56
14	Structure of detergent-activated BAK dimers derived from the inert monomer. <i>Molecular Cell</i> , 2021, 81, 2123-2134.e5.	4.5	26
15	BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia. <i>Blood Advances</i> , 2021, 5, 2550-2562.	2.5	9
16	Dynamic reconfiguration of pro-apoptotic BAK on membranes. <i>EMBO Journal</i> , 2021, 40, e107237.	3.5	20
17	Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis. <i>Nature Communications</i> , 2021, 12, 6783.	5.8	47
18	VDAC2 and the BCL-2 family of proteins. <i>Biochemical Society Transactions</i> , 2021, 49, 2787-2795.	1.6	23

#	ARTICLE	IF	CITATIONS
19	BAX, BAK, and BOK: A Coming of Age for the BCL-2 Family Effector Proteins. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036319.	2.3	106
20	Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. <i>EMBO Journal</i> , 2020, 39, e106275.	3.5	330
21	BAK core dimers bind lipids and can be bridged by them. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 1024-1031.	3.6	49
22	Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway. <i>ACS Chemical Biology</i> , 2020, 15, 2702-2713.	1.6	22
23	Crystal structure of the hinge domain of Smchd1 reveals its dimerization mode and nucleic acid-binding residues. <i>Science Signaling</i> , 2020, 13, .	1.6	12
24	Distinct pseudokinase domain conformations underlie divergent activation mechanisms among vertebrate MLKL orthologues. <i>Nature Communications</i> , 2020, 11, 3060.	5.8	47
25	A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. <i>Nature Communications</i> , 2020, 11, 3150.	5.8	75
26	Identification of MLKL membrane translocation as a checkpoint in necroptotic cell death using Monobodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8468-8475.	3.3	64
27	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020, 135, 773-777.	0.6	115
28	Relating SMCHD1 structure to its function in epigenetic silencing. <i>Biochemical Society Transactions</i> , 2020, 48, 1751-1763.	1.6	12
29	RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells. <i>ELife</i> , 2020, 9, .	2.8	16
30	A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. <i>Nature Chemical Biology</i> , 2019, 15, 1057-1066.	3.9	30
31	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e188-e191.	1.2	37
32	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019, 10, 2385.	5.8	139
33	Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of <i>Plasmodium falciparum</i> into human erythrocytes. <i>Cellular Microbiology</i> , 2019, 21, e13030.	1.1	34
34	Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. <i>EMBO Journal</i> , 2019, 38, .	3.5	66
35	Structure of <i>Plasmodium falciparum</i> Rh5-CyRPA-Ripr invasion complex. <i>Nature</i> , 2019, 565, 118-121.	13.7	74
36	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019, 9, 342-353.	7.7	306

#	ARTICLE	IF	CITATIONS
37	The Structural Basis of Necroptotic Cell Death Signaling. <i>Trends in Biochemical Sciences</i> , 2019, 44, 53-63.	3.7	125
38	The brace helices of MLKL mediate interdomain communication and oligomerisation to regulate cell death by necroptosis. <i>Cell Death and Differentiation</i> , 2018, 25, 1567-1580.	5.0	66
39	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
40	Embryogenesis and Adult Life in the Absence of Intrinsic Apoptosis Effectors BAX, BAK, and BOK. <i>Cell</i> , 2018, 173, 1217-1230.e17.	13.5	155
41	Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P 2 position of PEXEL peptidomimetics. <i>European Journal of Medicinal Chemistry</i> , 2018, 154, 182-198.	2.6	26
42	Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)â€™LRR oligomerization interface. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1956-1967.e6.	1.5	52
43	CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7783-7788.	3.3	55
44	Ensemble Properties of Bax Determine Its Function. <i>Structure</i> , 2018, 26, 1346-1359.e5.	1.6	34
45	Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis. <i>Nature Communications</i> , 2018, 9, 2422.	5.8	154
46	The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation. <i>Seminars in Cell and Developmental Biology</i> , 2017, 72, 152-162.	2.3	178
47	Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design. <i>Molecular Cell</i> , 2017, 68, 659-672.e9.	4.5	57
48	Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1298-1303.	1.3	23
49	Physiological restraint of Bak by Bcl-x_L is essential for cell survival. <i>Genes and Development</i> , 2016, 30, 1240-1250.	2.7	40
50	Preparing Samples for Crystallization of Bcl-2 Family Complexes. <i>Methods in Molecular Biology</i> , 2016, 1419, 213-229.	0.4	18
51	Multiple Plasmodium falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes. <i>Journal of Biological Chemistry</i> , 2016, 291, 7703-7715.	1.6	70
52	The hinge domain of the epigenetic repressor Smchd1 adopts an unconventional homodimeric configuration. <i>Biochemical Journal</i> , 2016, 473, 733-742.	1.7	19
53	A tale of two domains â€™ a structural perspective of the pseudokinase, <sc>MLKL</sc>. <i>FEBS Journal</i> , 2015, 282, 4268-4278.	2.2	24
54	Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 590-596.	3.6	93

#	ARTICLE	IF	CITATIONS
55	Genome-wide binding and mechanistic analyses of Smchd1-mediated epigenetic regulation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3535-44.	3.3	83
56	Transmembrane Complexes of DAP12 Crystallized in Lipid Membranes Provide Insights into Control of Oligomerization in Immunoreceptor Assembly. Cell Reports, 2015, 11, 1184-1192.	2.9	20
57	The Merozoite Surface Protein 1 Complex Is a Platform for Binding to Human Erythrocytes by Plasmodium falciparum. Journal of Biological Chemistry, 2014, 289, 25655-25669.	1.6	45
58	Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochemical Journal, 2014, 457, 369-377.	1.7	92
59	Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4076-85.	3.3	111
60	NMR studies of interactions between Bax and BH3 domain-containing peptides in the absence and presence of CHAPS. Archives of Biochemistry and Biophysics, 2014, 545, 33-43.	1.4	11
61	Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature Reviews Molecular Cell Biology, 2014, 15, 49-63.	16.1	2,444
62	Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15072-15077.	3.3	484
63	Further Insights into the Effects of Pre-organizing the BimBH3 Helix. ACS Chemical Biology, 2014, 9, 838-839.	1.6	26
64	De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-X _L : Synthesis, Structural and Biochemical Characterization. Journal of Medicinal Chemistry, 2014, 57, 1323-1343.	2.9	33
65	Structure-Guided Rescaffolding of Selective Antagonists of BCL-X _L . ACS Medicinal Chemistry Letters, 2014, 5, 662-667.	1.3	37
66	Bak Core and Latch Domains Separate during Activation, and Freed Core Domains Form Symmetric Homodimers. Molecular Cell, 2014, 55, 938-946.	4.5	140
67	Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity. ACS Medicinal Chemistry Letters, 2014, 5, 1088-1093.	1.3	242
68	Structural, kinetic and computational investigation of Vitis vinifera DHDPS reveals new insight into the mechanism of lysine-mediated allosteric inhibition. Plant Molecular Biology, 2013, 81, 431-446.	2.0	30
69	The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism. Immunity, 2013, 39, 443-453.	6.6	958
70	Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis. Cell, 2013, 152, 519-531.	13.5	491
71	Structure-guided design of a selective BCL-XL inhibitor. Nature Chemical Biology, 2013, 9, 390-397.	3.9	324
72	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X _L . Journal of Medicinal Chemistry, 2013, 56, 5514-5540.	2.9	60

#	ARTICLE	IF	CITATIONS
73	Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity. <i>ACS Chemical Biology</i> , 2013, 8, 297-302.	1.6	123
74	Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor β 1. <i>Biochemical Journal</i> , 2013, 451, 165-175.	1.7	11
75	Insights into Duffy Binding-like Domains through the Crystal Structure and Function of the Merozoite Surface Protein MSPDBL2 from <i>Plasmodium falciparum</i> . <i>Journal of Biological Chemistry</i> , 2012, 287, 32922-32939.	1.6	34
76	The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. <i>Immunity</i> , 2012, 36, 646-657.	6.6	272
77	Cytosolic Bax. <i>Journal of Biological Chemistry</i> , 2012, 287, 9112-9127.	1.6	29
78	Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1914-1926.	2.9	62
79	Catalytic mechanism and cofactor preference of dihydrodipicolinate reductase from methicillin-resistant <i>Staphylococcus aureus</i> . <i>Archives of Biochemistry and Biophysics</i> , 2011, 512, 167-174.	1.4	19
80	Molecular biology of Bax and Bak activation and action. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 521-531.	1.9	415
81	Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes Apoptosis. <i>Journal of Biological Chemistry</i> , 2011, 286, 7123-7131.	1.6	96
82	Bcl-2 Family Proteins as Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2010, 16, 3132-3148.	0.9	32
83	Crystal Structure of the Entire Ectodomain of gp130. <i>Journal of Biological Chemistry</i> , 2010, 285, 21214-21218.	1.6	78
84	Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands. <i>Journal of Biological Chemistry</i> , 2009, 284, 30508-30517.	1.6	79
85	High-Resolution Structural Characterization of a Helical α -Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-2. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 4318-4322.	7.2	143
86	Bak Activation for Apoptosis Involves Oligomerization of Dimers via Their α 6 Helices. <i>Molecular Cell</i> , 2009, 36, 696-703.	4.5	200
87	BCL-2 family antagonists for cancer therapy. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 989-1000.	21.5	549
88	Structural Plasticity Underpins Promiscuous Binding of the Prosurvival Protein A1. <i>Structure</i> , 2008, 16, 818-829.	1.6	97
89	A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. <i>Journal of Cell Biology</i> , 2008, 180, 341-355.	2.3	157
90	Structural insights into the degradation of Mcl-1 induced by BH3 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6217-6222.	3.3	397

#	ARTICLE	IF	CITATIONS
91	Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. <i>Science</i> , 2007, 315, 856-859.	6.0	1,021
92	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006, 10, 389-399.	7.7	1,149
93	Studies of structural changes in the M2 proton channel of influenza A virus by tryptophan fluorescence. <i>Virus Research</i> , 2004, 99, 57-61.	1.1	32
94	A Model for the Cytoplasmic Domain of the Influenza A Virus M2 Channel by Analogy to the HIV-1 Vpu Protein. <i>Protein and Peptide Letters</i> , 2002, 9, 495-502.	0.4	8
95	IDENTIFICATION OF REGIONS WITHIN THE THIRD FNIII-LIKE DOMAIN OF THE IL-5R α INVOLVED IN IL-5 INTERACTION. <i>Cytokine</i> , 2000, 12, 867-873.	1.4	2
96	Identification of residues involved in binding of IL5 to β 2m using β 2IL3 and β 2m chimeras. <i>FEBS Letters</i> , 1999, 460, 99-102.	1.3	2